<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39415865</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2251-6093</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Iranian journal of public health</Title><ISOAbbreviation>Iran J Public Health</ISOAbbreviation></Journal><ArticleTitle>Investigating the Potential Impact of CCR5-Δ32 Variant on COVID-19 Outcome: A Case-Control Study in Iranian Population.</ArticleTitle><Pagination><StartPage>1864</StartPage><EndPage>1870</EndPage><MedlinePgn>1864-1870</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.18502/ijph.v53i8.16292</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The impact of CCR5-Δ32 on COVID-19 outcomes has been the focus of much research. This genetic variant may protect against SARS-CoV-2 infection, while others have produced conflicting results. Given the controversial results of previous research on different populations, we aimed to investigate the possible association between the CCR5-Δ32 variant and COVID-19 severity in an Iranian population.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This case-control study was conducted between 25<sup>th</sup> of April till 10<sup>th</sup> of October 2021 at Rasoul Akram Hospital of Iran University of Medical Sciences, Tehran, Iran. We investigated the association between CCR5-Δ32 genotype and COVID-19 severity in 200 unrelated Iranian patients. The patients were divided into 2 groups: 100 patients with severe COVID-19 (case group) and 100 patients with mild COVID-19 (control group). Genotyping of CCR5-Δ32 was performed using the polymerase chain reaction (PCR) technique.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The frequency of CCR5-Δ32 allele was 11 in the case group and 16 in the control group. However, no significant association was found between this genetic variant and the clinical outcomes of COVID-19.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The CCR5-Δ32 variant cannot serve as a reliable predictive factor for identifying individuals prone to developing severe COVID-19 in Iranian population. Additionally, targeting CCR5 would not be a viable treatment approach for COVID-19 in Iranians.</AbstractText><CopyrightInformation>Copyright© 2024 Mashayekhi et al. Published by Tehran University of Medical Sciences.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mashayekhi</LastName><ForeName>Parisa</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omrani</LastName><ForeName>Mir Davood</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amini</LastName><ForeName>Asma Olhosna</ForeName><Initials>AO</Initials><AffiliationInfo><Affiliation>Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omrani</LastName><ForeName>Mohammad Amin</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milani</LastName><ForeName>Shahla Ganbari</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Department of Genetics, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Iran</Country><MedlineTA>Iran J Public Health</MedlineTA><NlmUniqueID>7505531</NlmUniqueID><ISSNLinking>2251-6085</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Iranian population</Keyword><Keyword MajorTopicYN="N">Severe COVID-19</Keyword><Keyword MajorTopicYN="N">Virus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>4</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39415865</ArticleId><ArticleId IdType="pmc">PMC11475173</ArticleId><ArticleId IdType="doi">10.18502/ijph.v53i8.16292</ArticleId><ArticleId IdType="pii">IJPH-53-1864</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen N, Zhou M, Dong X, et al. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 395 (10223):507–513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatmawati F, Mulyanti S. (2023). Risk Factors Associated with the Severity of COVID-19. Malays J Med Sci, 30 (3):84–92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10325129</ArticleId><ArticleId IdType="pubmed">37425387</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad FB, Cisewski JA, Miniño A, Anderson RN. (2021). Provisional mortality data—united states, 2020. MMWR Morb Mortal Wkly Rep, 70(14):519–522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8030985</ArticleId><ArticleId IdType="pubmed">33830988</ArticleId></ArticleIdList></Reference><Reference><Citation>Proportions V  (2022). COVID Data Tracker. https://covid.cdc.gov/covid-data-tracker/#data-tracker-home</Citation></Reference><Reference><Citation>Velavan TP, Pallerla SR, Rüter J, Augustin Y, Kremsner PG, Krishna S, Meyer CG. (2021). Host genetic factors determining COVID-19 susceptibility and severity. EBioMedicine, 72: 103629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8512556</ArticleId><ArticleId IdType="pubmed">34655949</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlsen TH. (2022). Understanding COVID-19 through genome-wide association studies. Nat Genet, 54 (4):368–369.</Citation><ArticleIdList><ArticleId IdType="pubmed">35410380</ArticleId></ArticleIdList></Reference><Reference><Citation>Glessner JT, Chang X, Mentch F, Qu H, Abrams DJ, Thomas A, Sleiman P, Hakonarson H. (2022). COVID-19 in pediatrics: Genetic susceptibility. Front Genet, 13:928466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9425045</ArticleId><ArticleId IdType="pubmed">36051697</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellinghaus D. (2020). Genomewide association study of severe Covid-19 with respiratory failure. N Engl J Med, 383(16):1522–1534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7315890</ArticleId><ArticleId IdType="pubmed">32558485</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien H-C, Chan P-C, Tu C-C, Day Y-J, et al. (2018). Importance of PLC-dependent PI3K/AKT and AMPK signaling in RANTES/CCR5 mediated macrophage chemotaxis. Chin J Physiol, 61 (5):266–279.</Citation><ArticleIdList><ArticleId IdType="pubmed">30384400</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Qin L, Zhang P, Li K, et al. (2020). Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. JCI Insight, 5 (13): e139834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7406242</ArticleId><ArticleId IdType="pubmed">32501293</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellwanger JH, Kulmann-Leal B, de Lima Kaminski V, et al. (2020). Beyond HIV infection: neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases. Virus Res, 286:198040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7260533</ArticleId><ArticleId IdType="pubmed">32479976</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellwanger JH, Kaminski VdL, Rodrigues AG, et al. (2020). CCR5 and CCR5Δ32 in bacterial and parasitic infections: Thinking chemokine receptors outside the HIV box. Int J Immunogenet, 47 (3):261–285.</Citation><ArticleIdList><ArticleId IdType="pubmed">32212259</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Mateos E, Tarancon-Diez L, Alvarez-Rios AI, et al. (2018). Association of heterozygous CCR5Δ32 deletion with survival in HIV-infection: A cohort study. Antiviral Res, 150:15–19.</Citation><ArticleIdList><ArticleId IdType="pubmed">29221798</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcon A, Cuevas MT, Rodriguez-Frandsen A, et al. (2015). CCR5 deficiency predisposes to fatal outcome in influenza virus infection. J Gen Virol, 96 (8):2074–2078.</Citation><ArticleIdList><ArticleId IdType="pubmed">25918237</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass WG, McDermott DH, Lim JK, et al. (2006). CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med, 203 (1):35–40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2118086</ArticleId><ArticleId IdType="pubmed">16418398</ArticleId></ArticleIdList></Reference><Reference><Citation>Panda AK, Padhi A, Prusty BAK. (2020). CCR5 Δ32 minorallele is associated with susceptibility to SARS-CoV-2 infection and death: An epidemiological investigation. Clin Chim Acta, 510:60–61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7347491</ArticleId><ArticleId IdType="pubmed">32653483</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BK, Seethamraju H, Dhody K, et al. (2021). CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARSCoV2 RNA in plasma by day 14. Int J Infect Dis, 103:25–32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7654230</ArticleId><ArticleId IdType="pubmed">33186704</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandford AJ, Zhu S, Bai TR, et al. (2001). The role of the CC chemokine receptor-5 Δ32 polymorphism in asthma and in the production of regulated on activation, normal T cells expressed and secreted. J Allergy Clin Immunol, 108 (1):69–73.</Citation><ArticleIdList><ArticleId IdType="pubmed">11447384</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishak A, Mehendale M, AlRawashdeh MM, et al. (2022). The association of COVID-19 severity and susceptibility and genetic risk factors: A systematic review of the literature. Gene, 836:146674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9195407</ArticleId><ArticleId IdType="pubmed">35714803</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein RS. (2008) A moving target: the multiple roles of CCR5 in infectious diseases. J Infect Dis, 197(2):183–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18179384</ArticleId></ArticleIdList></Reference><Reference><Citation>Jasinska AJ, Pandrea I, Apetrei C. (2022). CCR5 as a coreceptor for human immunodeficiency virus and simian immunodeficiency viruses: A prototypic love-hate affair. Front Immunol, 13:835994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8829453</ArticleId><ArticleId IdType="pubmed">35154162</ArticleId></ArticleIdList></Reference><Reference><Citation>Čizmarević NS, Kapović M, Rončević D, Ristić S. (2021). Could the CCR5-Δ32 mutation be protective in SARS-CoV-2 infection? Physiol Res, 70 (S 2):S249–S252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8884372</ArticleId><ArticleId IdType="pubmed">34913355</ArticleId></ArticleIdList></Reference><Reference><Citation>Gómez J, Cuesta-Llavona E, Albaiceta GM, et al. (2020). The CCR5-delta32 variant might explain part of the association between COVID-19 and the chemokine-receptor gene cluster. medRxiv, doi: 10.1101/2020.11.02.20224659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.11.02.20224659</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubacek JA, Dusek L, Majek O, et al. (2021). CCR5Δ32 deletion as a protective factor in Czech first-wave COVID-19 subjects. Physiol Res, 70 (1):111–115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8820511</ArticleId><ArticleId IdType="pubmed">33728925</ArticleId></ArticleIdList></Reference><Reference><Citation>Čizmarević NS, Tota M, Ristić S. (2020). Does the CCR5-Δ32 mutation explain the variable coronavirus-2019 pandemic statistics in Europe? Croat Med J, 61 (6):525–526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7821361</ArticleId><ArticleId IdType="pubmed">33410299</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernas SN, Baldauf H, Wendler S, et al. (2021). CCR5Δ32 mutations do not determine COVID-19 disease course. Int J Infect Dis, 105:653–655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7923852</ArticleId><ArticleId IdType="pubmed">33667698</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin P. (2021). Immune determinants of COVID-19 disease presentation and severity. Nat Med, 27 (1):28–33.</Citation><ArticleIdList><ArticleId IdType="pubmed">33442016</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajaj V, Gadi N, Spihlman AP, et al. (2021). Aging, immunity, and COVID-19: how age influences the host immune response to coronavirus infections? Front Physiol, 11:571416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7835928</ArticleId><ArticleId IdType="pubmed">33510644</ArticleId></ArticleIdList></Reference><Reference><Citation>Statsenko Y, Al Zahmi F, Habuza T, et al. (2022). Impact of age and sex on COVID-19 severity assessed from radiologic and clinical findings. Front Cell Infect Microbiol, 11: 777070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8913498</ArticleId><ArticleId IdType="pubmed">35282595</ArticleId></ArticleIdList></Reference><Reference><Citation>Karimi Z, Masjedi F, Doostkam A, Roozbeh J, Malekmakan L. (2022). Investigating the Association between Gender and Age Distribution with Severity of COVID-19: A Single-Center Study from Southern Iran. Women’s Health Bulletin, 9 (4):207–215.</Citation></Reference><Reference><Citation>Barek MA, Aziz MA, Islam MS. (2020). Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: A meta-analysis with 55 studies and 10014 cases. Heliyon, 6 (12): e05684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737518</ArticleId><ArticleId IdType="pubmed">33344791</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>